Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Non-Current Assets (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Other Non-Current Assets data on record, last reported at $358000.0 in Q3 2025.

  • For Q3 2025, Other Non-Current Assets fell 4.28% year-over-year to $358000.0; the TTM value through Sep 2025 reached $358000.0, down 4.28%, while the annual FY2024 figure was $365000.0, 1.11% up from the prior year.
  • Other Non-Current Assets reached $358000.0 in Q3 2025 per NWBO's latest filing, down from $370000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.1 million in Q2 2021 and bottomed at $339000.0 in Q3 2022.
  • Average Other Non-Current Assets over 5 years is $507210.5, with a median of $363000.0 recorded in 2024.
  • Peak YoY movement for Other Non-Current Assets: soared 44.77% in 2021, then plummeted 68.71% in 2022.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.0 million in 2021, then crashed by 66.7% to $345000.0 in 2022, then rose by 4.64% to $361000.0 in 2023, then rose by 1.11% to $365000.0 in 2024, then decreased by 1.92% to $358000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $358000.0 in Q3 2025, $370000.0 in Q2 2025, and $367000.0 in Q1 2025.